Philadelphia Chapter Meeting
Online Registration Closed: Onsite Registration Available
DATE & TIME
Thursday, February 23, 2012
6:00 PM - 9:00 PM
LOCATION
Yangming
Conestoga & Haverford Roads
(1051 Conestoga Road)
Bryn Mawr, PA 19010
(610) 527-3200
TITLE
Lessons Learned in Licensing: The Weird, Wild and Wonderful
DESCRIPTION
Several LES Philadelphia Chapter members will share their licensing experiences in an interactive session. Licensing veteran Bob Bramson will share his experiences and moderate the discussion. The meeting will also profile deals by Pierre Gosselin, Ph. D., Senior Director, Business Development, Shire Pharmaceuticals and Kevin Taylor, former VP of Business Development at Adolor Corporation. We believe these lessons learned will be directly relevant to other local members and we invite everyone to come an join the discussion. If you are interested in sharing your licensing lesson learned at this meeting you can contact us in advance at the Philadelphia Chapter Facebook Event Page or send it directly to us via e-mail or simply come to the meeting and share your experience.
DEAL PROFILES
Pierre Gosselin, Ph. D., Senior Director, Business Development, Shire Pharmaceuticals, Inc.
In August 2010, Shire Pharmaceuticals, Inc. expanded its GI business through the acquisition of Movetis, a Belgian-based GI specialty pharmaceuticals company that focuses on treatments targeting gastrointestinal conditions with a high unmet medical need. This acquisition further expanded Shire’s GI market presence in Europe with the recently approved Resolor (prucalopride), a product indicated for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. The transaction also brought a pipeline of GI motility products with regional or global rights and at various stages of development, expanding the depth of Shire’s GI portfolio. However, the rights to prucalopride outside of Europe, including the US, were held by Johnson & Johnson. While US only rights to prucalopride were not strategic to Shire, adding US to the already licensed territory. Following negotiations with J&J, Shire was able to acquire the US rights to prucalopride in January 2012 and will pursue its development in the US as well.
Kevin Taylor,
Former Vice President of Business Development,
Adolor Corporation
Adolor completed a in-licensing transaction with Eli Lilly and company in an effort to rebuild its pipeline and company valuation. The compound known as ADL5945, or to Lilly as OpRA III, is a potent small molecule opioid receptor antagonist that Lilly had taken through Phase 1 human clinical development. Adolor completed Phase 2 clinical development of ADL5945 in August with very positive efficacy results and a compelling tolerability profile which in part formed the basis for the company’s acquisition by Cubist Pharmaceuticals in December 2011. One of the challenges in negotiating the license agreement with Lilly was that the intellectual property that covered ADL5945 also covered another compound, OpRA II, that Lilly had in clinical development at the time. This impacted a number of provisions in the license agreement including patent prosecution rights, diligence provisions and eligibility for Hatch Waxman patent extension coverage and supplemental protection certificates.
Robert S. Bramson, Partner, Bramson & Pressman
Bob has negotiated numerous licenses over the years and he will share lesson learned from several interesting experiences. Bob’s will profile his weirdest negotiation – As a young attorney, he had just started working for the Scott Paper Legal Department. He was involved in a negotiation with Hercules Chemical for a collaboration on a joint R&D/licensing program. What Bob heard in his first meeting blew his mind. Bob will also share his biggest ethical challenge – He was Licensing Counsel for a major drug company and was approached by a young accountant at the company who said, “I think that we underpaid a license agreement royalty by $20 million. What should we do?” Come to the Philadelphia Chapter meeting to learn the rest of Bob’s stories.
SCHEDULE
6:00 PM - 7:15 PM: Networking and Cocktail Reception
7:15 PM - 8:30 PM: Group Discussion
8:30 PM - 9:00 PM: Networking and Coffee
ONLINE REGISTRATION
LES Members: $40
Non-Members: $45
Onsite: $50
DIRECTIONS AND PARKING:
Route 476 to Exit 13. Turn right on to Lancaster Avenue (Route 30). Go approximately 1.5 miles and turn right on to County Line Road (McDonalds on left). Go approximately .25 miles and turn right into the Yangming parking lot.
Registration Deadline: Wednesday, February 22, 4 PM
Onsite Registration Available
CANCELLATION POLICY
No refunds after February 22
Substitutions are permitted
DRESS CODE
Business or Business Casual
SPEAKER BIOGRAPHIES
Robert S. Bramson
Bob has fifty years of licensing experience. He is a partner of the law firm of Bramson & Pressman. Bob was founding CEO of InterDigital Patents Corporation, a patent licensing company; Vice President and General Patent and Technology Counsel for Unisys Corporation; Partner and Head, Computer and Technology Law Group, Schnader, Harrison, Segal & Lewis; IP Counsel for Scott Paper Company; and Licensing Counsel for Abbott Laboratories. Bob taught IP Licensing Law and Patent Law at Temple University School of Law and Rutgers Law School for twenty five years. He holds degrees from Rensselaer Polytechnic Institute (B.M.E.) and Georgetown University Law Center (LL.B.), and attended the University of Chicago Graduate School of Business.
Pierre Gosselin, Ph. D.
Dr. Gosselin has been with Shire Pharmaceuticals since 2001 with current responsibilities for business development activities in Shire's Specialty Pharma business. He previously held various positions with increased responsibilities within Shire’s Business Development. Prior to joining Shire, Dr. Gosselin was Scientific Analyst in R&D and Business Development at BioChem Pharma, Inc. (Laval, Canada). He was also Acting Director, Extramural Research at BioChem with responsibility for global University collaborations and licensing. Through his professional career, Dr. Gosselin was involved in a number of partnerships including in- and out-license and co-promotion agreements as well as M&As. Dr. Gosselin received a B.Sc. and a M.Sc. in microbiology from Laval University and a Ph.D. in experimental Medicine from McGill University before working as a visiting fellow at the National Cancer Institute (NIH) in Maryland from 1995 to 1999.
Kevin Taylor
Kevin Taylor was most recently the Vice President of Business Development at Adolor Corporation. In his seven years at Adolor, he conclude multiple licensing and collaboration agreements with academic institutions, small biotech companies, Eli Lilly and Company, Pfizer and Schering-Plough Corporation. His activities and tenure at Adolor culminated in the company's successful acquisition by Cubist Pharmaceuticals in December 2011. Previously, he held senior business development and commercial operations roles at Codexis, Elan and Zeneca. Kevin has undergraduate degree in Polymer Science and Chemistry from the Pennsylvania State University and masters degree in Management from the University of Pennsylvania.